Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)

NCT06730412 is registered in ClinicalTrials.gov with Massachusetts Eye and Ear Infirmary as lead sponsor.

NCT NCT06730412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06730412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)
Lead sponsor
Massachusetts Eye and Ear Infirmary
Phase
Observational
Overall status
Completed
Start date
August 1, 2020
Completion date
October 31, 2024
Enrollment
103 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hpv positive oropharyngeal squamous cell carcinoma